While the inhibition of JAKs is an established strategy for the treatment of several immune and nonimmune diseases, STAT inhibitors—which act by inhibiting phosphorylation and dimerisation or by inducing degradation of STAT proteins—are still under investigation, mostly in the cancer field. Here, SOAT1 is linked to cancer.